U.S. patent application number 11/041270 was filed with the patent office on 2005-12-15 for bioimplant formulation.
This patent application is currently assigned to Peptech Limited. Invention is credited to Rathjen, Deborah Ann, Trigg, Timothy Elliot, Walsh, John Desmond.
Application Number | 20050276854 11/041270 |
Document ID | / |
Family ID | 27158088 |
Filed Date | 2005-12-15 |
United States Patent
Application |
20050276854 |
Kind Code |
A1 |
Trigg, Timothy Elliot ; et
al. |
December 15, 2005 |
Bioimplant formulation
Abstract
A pharmaceutical and/or veterinary formulation comprising about
2-30% (w/w) (on an active basis) of at least one active agent,
about 0.5-20.0% (w/w) of a pore-forming agent and the balance
stearin. Such formulations provide sustained release of the at
least one active agent in humans and other animals for periods of 7
days up to about 2 years.
Inventors: |
Trigg, Timothy Elliot;
(Warrawee, AU) ; Walsh, John Desmond; (Curl Curl,
AU) ; Rathjen, Deborah Ann; (Thornleigh, AU) |
Correspondence
Address: |
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON
VA
22203
US
|
Assignee: |
Peptech Limited
North Ryde
AU
|
Family ID: |
27158088 |
Appl. No.: |
11/041270 |
Filed: |
January 25, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11041270 |
Jan 25, 2005 |
|
|
|
09743059 |
Feb 12, 2001 |
|
|
|
6913761 |
|
|
|
|
09743059 |
Feb 12, 2001 |
|
|
|
PCT/AU99/00585 |
Jul 20, 1999 |
|
|
|
Current U.S.
Class: |
424/473 ;
514/10.3; 514/10.4 |
Current CPC
Class: |
A61K 9/70 20130101; A61K
9/0024 20130101 |
Class at
Publication: |
424/473 ;
514/015 |
International
Class: |
A61K 038/09; A61K
009/64; A61K 009/24 |
Foreign Application Data
Date |
Code |
Application Number |
Jul 20, 1998 |
AU |
PP4730 |
Jul 20, 1998 |
AU |
PP4731 |
May 13, 1999 |
AU |
PQ0324 |
Claims
1-40. (canceled)
41. A pharmaceutical and/or veterinary formulation comprising about
2-30% (w/w) (on an active basis) of at least one active agent,
about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin
and an organic salt, and the balance stearin.
42. A formulation according to claim 41, wherein the formulation
comprises about 5-10% (w/w) (on an active basis) of the at least
one active agent, about 1.0-10.0% (w/w) of the pore-forming agent
and the balance stearin.
43. A formulation according to claim 41, wherein the formulation
comprises about 5-10% (w/w) (on an active basis) of the at least
one active agent. about 2.0-5.0% (w/w) of the pore-forming agent
and the balance stearin.
44. A formulation according to claim 41, wherein the pore-forming
agent comprises lecithin and sodium acetate.
45. A formulation according to claim 41, wherein the at least one
active agent is selected from peptides, polypeptides, proteins and
nucleic acid compounds and derivatives.
46. A formulation according to claim 41, wherein the at least one
active agent is selected from GnRII agonists.
47. A formulation according to claim 46, wherein the GnRH
agonist(s) is selected from deslorelin, eulexin, goserelin,
leuprolide. dioxalan derivatives, triptorelin, mieterelin,
buserelin, histerlin, nafarelin, lutrelm, leuprorelin and LIIRII
analogues.
48. A formulation according to claim 46, wherein the GnRII
agonist(s) is deslorelin and the pore-forming agent comprises
lecithin and sodium acetate.
49. A formulation according to claim 41, wherein the at least one
active agent has a log octanol/water partition coefficient (log P)
in the range of 5.0 to -3.0.
50. A formulation according to claim 49, wherein the at least one
active agent has a log octanol/water partition coefficient (log P)
in the range 1.0 to -3.0.
51. A formulation according to claim 41, wherein the formulation is
in the form of free flowing beads or rods.
52. A method of treating a disease or condition in a human or other
animal, the method comprising administering to the human or other
animal a formulation according to claim 41.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to pharmaceutical and/or
veterinary formulations for the sustained release of at least one
active agent. Preferred active agents include
gonadotropin-releasing hormone (GnRH) agonists (e.g. deslorelin),
GnRH antagonists (e.g. cetrorelix), somatostatin analogues (e.g.
somatostatin-14 and octreotide), lipid lowering agents (e.g.
simvastatin), cyclosporins (e.g. cyclosporin A), angiotensin
converting-enzyme inhibitors (e.g. captopril), calcitonins,
substance P antagonists, painkillers (e.g. morphine), opioid
antagonists (e.g. naltrexone), anti-depressants (e.g. venlafaxine)
and non-steroidal anti-inflammatory agents (e.g. naproxen
sodium).
BACKGROUND OF THE INVENTION
[0002] For reasons including improved efficacy of action and
reduced frequency of administration, there is considerable interest
in the development of pharmaceutical and veterinary formulations
capable of controllably releasing active agents for sustained
periods (e.g. up to 6 months or more). Types of pharmaceutical
agents that would particularly benefit from the development of such
formulations are those which are typically administered by patients
themselves over long periods (e.g. insulin for diabetes treatment,
and gonadotropin-releasing hormone (GnRH) agonists for reproductive
control and treatment of sex hormone-dependent diseases and
conditions) and require high levels of patient compliance. In the
veterinary context, sustained release formulations would reduce the
stress often caused to the animal and veterinarian/owner alike by
the need for repeated administration of active agents.
[0003] The present applicant's have found that sustained release of
at least one active agent in humans and other animals for periods
of 7 days up to about 2 years, can be achieved by using a solid
formulation comprising stearin as an excipient in combination with
a substance which, while not wishing to be bound by theory, appears
to form pores and/or cracks in the excipient to enable the release
of the active agent(s).
SUMMARY OF THE INVENTION
[0004] Thus, in a first aspect, the present invention provides a
pharmaceutical and/or veterinary formulation comprising about 2-30%
(w/w) (on an active basis) of at least one active agent, about
0.5-20.0% (w/w) of a pore-forming agent and the balance
stearin.
[0005] In a preferred embodiment, the formulation comprises about
5-10% (w/w) (on an active basis) of at least one active agent,
about 1.0-10.0% (w/w) of a pore-forning agent and the balance
stearin.
[0006] In a more preferred embodiment, the formulation comprises
about 5-10% (wlw) (on an active basis) of at least one active
agent, about 2.0-5.0% (w/w) of a pore-forming agent and the balance
stearin.
[0007] In a second aspect, the present invention provides a method
of treating a disease or condition in a human or other animal, the
method comprising administering to the human or other animal the
formulation of the first aspect of the invention.
DETAILED DISCLOSURE OF THE INVENTION
[0008] The at least one active agent utilised in the formulation of
the present invention, may be selected from agents having
pharmaceutical or veterinary significance and may be any or a
combination of peptides (e.g. hormones and antigens), polypeptides
and proteins, and nucleic acid compounds and derivatives such as
DNA and RNA
[0009] Preferred active agents include:
[0010] (1) GnRH Agonists
[0011] Particularly preferred GnRH peptide agonists are deslorelin
(described in U.S. Pat. No. 4,218,439), eulexin (described in
FR7923545, WO 86/01105 and PT100899), goserelin (described in U.S.
Pat. No. 4,100,274, U.S. Pat. No. 4,128,638, GB9112859 and
GB9112825), leuprolide (described in U.S. Pat. No. 4,490,291, U.S.
Pat. No. 3,972,859, U.S. Pat. No. 4,008,209, U.S. Pat. No.
4,005,063, DE2509783 and U.S. Pat. No. 4,992,421), dioxalan
derivatives such as are described in EP 413209, triptorelin
(described in U.S. Pat. No. 4,010,125, U.S. Pat. No. 4,018,726,
U.S. Pat. No. 4,024,121, EP 364819 and U.S. Pat. No. 5,258,492),
meterelin (described in EP 23904), buserelin (described in U.S.
Pat. No. 4,003,884, U.S. Pat. No. 4,118,483 and U.S. Pat. No.
4275001), histrelin (described in EP217659), nafarelin (described
in U.S. Pat. No. 4,234,571, W093/15722 and EP52510), lutrelin
(described in U.S. Pat. No. 4,089,946), leuprorelin (described in
Plosker et al., Drugs 48 930-967, 1994) and LHRH analogues such as
are described in EP181236, U.S. Pat. No. 4,608,251, U.S. Pat. No.
4,656,247, U.S. Pat. No. 4,642,332, U.S. Pat. No. 4,010,149, U.S.
Pat. No. 3,992,365 and U.S. Pat. No. 4,010,149. The disclosures of
each the patent specifications and papers referred to above are
incorporated herein by reference.
[0012] The most preferred GnRH agonists are goserelin, deslorelin,
leuprorelin, triptorelin, meterelin, buserelin, histrelin,
nafarelin and combinations thereof. The formulae of these compounds
are provided below:
[0013] Goserelin
C.sub.59H.sub.84N.sub.18O.sub.14C.sub.2H.sub.4O.sub.2
D-Ser(Bu.sup.t).sup.6Azgly.sup.10-LHRH Acetate
3-[5-oxo-L-prolyl-L-trypto-
phyl-L-seryl-L-tyrosyl-(3-O-tert-butyl)-D-seryl-L-leucyl-L-arginyl-L-proly-
l]cabazamide acetate.
[0014] Deslorelin G-D-tryptophan-9-(N-ethyl-L
prolinamide)-10-deglycinamid- e P
Glutamine-Histidine-Tryptophan-Serine-Tyrosine-D
Tryptophan-Leucine-Arginine-Proline-ethylamide.
[0015] Leuprorelin C.sub.59H.sub.84N.sub.16O.sub.12,
C.sub.2H.sub.4O.sub.2 Leuprorelin Acetate
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyro-
syl-D-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate.
[0016] Triptorelin C.sub.59H.sub.84N.sub.10O.sub.12,
C.sub.2H.sub.4O.sub.2 D-Trp.sup.6-LHRH
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-
-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide.
[0017] Meterelin Des
Gly.sup.10-2-methyl-D-Trp.sup.6-Pro-ethyl-amide.sup.9 LHRH.
[0018] Buserelin C.sub.60H.sub.86N.sub.16O.sub.13,
C.sub.2H.sub.4O.sub.2 D-Ser(Bu.sup.t).sup.8-Pro9-NEt LHRH Acetate
Oxo-L-prolyl-L-histidyl
L-tryptophyl-L-seryl-L-tyrosyl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-N--
ethyl-L-prolinamide acetate.
[0019] Histrelin
Pro-His-Trp-Ser-Tyr-Leu-D(N-benzyl)His-Arg-Pro-N-ethylami- de.
[0020] Nafarelin C.sub.66H.sub.83N.sub.17O.sub.13,
xC.sub.2H.sub.4O.sub.2y-
H.sub.2OOxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphth-
yl)-D-alanyl-L-leucyl-L-arginyl-N-ethyl-L-prolylglycinamide acetate
hydrate.
[0021] Formulations according to the invention which include a GnRH
agonist as the at least one active agent may be used for
controlling reproductive function or for the treatment of any
disease or condition wherein reduction of sex hormone (i.e.
testosterone or estradiol) levels over a prolonged period is
beneficial. Examples include prostrate cancer, ovarian and breast
cancer, benign hormone-dependent disorders such as endometriosis,
myoma and premenstrual tension, uterine fibroids, induction of
endometrial atrophy prior to surgery, suppression of germ cell
activity in chemotherapy, hirsutism, cyclic auditory dysfunction,
porphyria and precocious puberty ill children, benign prostatic
hypertension in dogs and for use in other conditions where
castration is known to have a beneficial clinical effect, including
restoration of T cell-mediated immunity.
[0022] (2) GnRH Antagonists
[0023] Particularly preferred GnRH antagonists are ramorelix
(L-prolone,1-(N2-(N-(N-(N-(N-(N-(N-(N-acetyl-3-(2-naphhthalenyl)-D-alanyl-
)-4-chloro-D-phenylalanyl)-D-tryptophyl)-L-seryl)-L-tyrosyl-O-(6-deoxy-alp-
ha-L-manntopyranosyl)-D-seryl)-L-leucyl)-L-arginyl)-2-(aminoacrbonyl)hyraz-
ide, teverelix
(D-alaninamide,N-acetyl-3-(2-naphthalenyl)-D-alayl-4-chloro-
-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(aminocarbon-
yl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl,
cetrorelix (D-Alaninamode,
N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylala-
nyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ol-L-l-
eucyl-L-arginyl-L-prolyl, ganirelix
(N--Ac-D-Nal,D-pCl-Phe,D-Pal,DhArg(Et)- 2,hArg(Et)2,D-Ala) GnRH,
alanex, abarelix (D-Alaninamide,N-acetyl-3-(2-nap-
hthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-ser-
yl-N-methyl-L-tyrosyl-D-asparainyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-p-
rolyl;
N--(S)-tetrahydrofuroyl-Gly-D2Nal-D4Ciphe-D3Pal-Ser-NmeTyr-D-lys(Ni-
c)-Leu-Lys(Isp)-Pro-D-Ala-NH2;
isopropyl-13-(N-benzyl-N-methaminomethyl)-7-
-(2,6-diflurobenzyl)-4,7-dihydro-2-(4-isobutyrylaminophenyl)-4-oxothieno(2-
,3-b)pyridine-5-carboxyatehydrochloride). Other preferred GnRH
antagonists are described in U.S. Pat. No. 5,110,904, U.S. Pat. No.
5,300,492, U.S. Pat. No. 5,807,983, U.S. Pat. No. 5,169,932, U.S.
Pat No. 5,296,468 and U.S. Pat. No. 5,502,035.
[0024] (3) Somatostatin Analogues
[0025] Particularly preferred somatostatin analogues include
somatostatin-14, octreotide, lanreotide and angiopeptin
cyclopeptides (U.S. Pat. No. 5,569,647).
[0026] Formulations according to the invention which include a
somatostatin analogue as the at least one active agent may be used
for treating, for example, hyperinsulinaemia and peptic ulcers.
[0027] (4) Lipid Lowering Agents
[0028] Particularly preferred lipid lowering agents include
compounds which inhibit HMG CoA reductase such as cerevastatin,
mevastatin, simvastatin, pravastatin and lovastatin.
[0029] Formulations according to the invention which includes these
agents may be used for treating, for example,
hyperlipoproteineamia.
[0030] (5) Cyclosporins
[0031] Preferred cyclosporins include naturally occurring
cyclospolins (e.g. as described by Dreyfuss et al., (1976) Europ.
J. Appl. Microbiol. Vol. 3: 125-133), and analogues (e.g. as
described by Wenger R. M. (1982), Chemistry of Cyclosporin A in
"Cyclosporin "A", White D. G. G. ed., Amsterdam; Elsevier).
[0032] Formulations according to the invention which include a
cyclosporin or cyclosporin analogue as the at least one active
agent may be used, for example, as immunosuppressive agents for
prophylaxis and treatment of organ rejection in allogeneic
transplants.
[0033] (6) Angiotensin Converting Enzyme Inhibitors
[0034] Preferred ACE inhibitors include captopril, enalapril,
trandolaprilate, perindoprilate, quinaprilate, fasidotril,
omapatrilate and lisinopril.
[0035] Formulations according to the invention which include such
agents may be used, for example, as antihypertensives.
[0036] (7) Calcitonins
[0037] Preferred calcitonins include human, salmon, and porcine
calcitonin. Analogues of these polypeptides may also be
suitable.
[0038] Formulations according to the invention which include
calcitonin or calcitonin analogues may be used for treatment of,
for example, hypercalcemia and for decreasing concentrations of
phosphate in patients suffering from hyperparathyroidism, vitamin D
intoxication, and osteolytic bone metastases.
[0039] (8) Substance P Antagonists
[0040] Preferred substance P antagonists include fragment 4-11
(i.e. Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH.sub.2 and variant forms),
fragment 5-11 (i.e. Gln-Gln-Phe-Phe-Gly-Leu-Met-NH.sub.2 and
variant forms), fragment 6-11 (i.e.
Gln-Phe-Phe-Gly-Leu-Met-NH.sub.2 and variant forms), fragment 7-11
(i.e. Phe-Phe-Gly-Leu-Met-NH.sub.2), fragment 8-11 (i.e.
Phe-Gly-Leu-Met-NH.sub.2) and fragment 9-11 (i.e.
Gly-Leu-Met-NH.sub.2). Other suitable substance P antagonists
include those described in the present applicant's co-pending
Australian Provisional Patent Application No. PP9008.
[0041] Formulations according to the invention which include
substance P antagonists may be used for treatment of cancer
including chemotherapy-induced nausea and vomiting, pain, allergy,
asthma, inflammatory conditions including inflammatory bowel
disease and depression.
[0042] (9) Painkillers
[0043] Preferred painkillers include opioids such as morphine,
levorphanol and meperidine (pethidine), and amide local
anaesthetics such as bupivacaine, lidocaine, etidocaine and
mepivacaine.
[0044] Formulations according to the invention which include such
painkilling agents may be used to treat acute pain (e.g. such as
that experienced by hip replacement patients) or chronic regional
pain.
[0045] (10) Opioid Antagonists
[0046] Preferred opioid antagonists include naltrexone, naloxone
and methadone.
[0047] Formulations according to the invention which include opioid
antagonists may be used for treatment of opioid dependency.
[0048] (11) Anti-Depressants
[0049] Preferred anti-depressants include venlafaxine,
triflupromazine, methotrimeprazine, promethazine, buspirone,
gepirone and fluoxetine (Prozac).
[0050] (12) Non-Steroidal Anti-Inflammatory Agents
[0051] Preferred non-steroidal anti-inflammatory agents include
naproxen sodium indomethacin, sulindac, tolmelin, acemetacin,
zomepirac, mefenamic acid, fenoprofen, flufenamic acid,
phenylbutazone, flurbiprofen, ketoprofen and axsain.
[0052] Formulations according to the invention which include
non-steroidal anti-inflammatory agents may be used for the
treatment of post-operative inflammation and inflammation
associated with, for example, rheumatoid arthritis.
[0053] (13) Miscellaneous
[0054] Other suitable active agents include paroxetine for
treatment of social anxiety disorder/social phobia, galanin
antagonists such as galanin fragment
1-13-Pro-Pro-Ala-Leu-Ala-Leu-Ala amide and galanin (1-13)-spantide
1 for treatment of obesity, eating disorders, depression and pain;
activin and inhibin fragments such as .alpha.-subunit fragment 1-32
and .beta.-fragment 67-94 for fertility control;
adrenocorticotropic hormone (ACTH) and variants and fragments for
treatment of West Syndrome and infantile spasms; growth hormone and
its analogues for replacement therapy in growth-hormone deficient
children; erythropoietin (EPO) and its analogues for treatment of
anaemia; endothelin antagonists for prevention of congestive heart
failure, prevention of acute renal failure and subarachnoid
haemorrhage, prevention and treatment of atherosclerosis, treatment
of hypertension, prevention of stroke and treatment of chronic
obstructive pulmonary disease; leptin and its agonists and
antagonists for treatment of obesity and eating disorders such as
anorexia nervosa, and for weight loss; thyrotropin releasing
hormone (TRH and its analogues (e.g. pGlu-His-Pro-Gly) for
treatment of, for example, epilepsy; and theophylline and its
analogues for the treatment of asthma, systemic capillary leak
syndrome and Parkinson's disease. Vaccine antigens, including DNA
encoding vaccine antigens, may also be delivered in a formulation
according to the present invention.
[0055] Formulations according to the invention may include a
combination of active agents. Examples of preferred combinations
(comprising "Agent 1" and "Agent 2") are shown in Table 1.
1 TABLE 1 Agent 1 Agent 2 HMG Co A reductase inhibitor Gemfibrozil
Non-steroidal anti-inflammatory agent Mycophenolate mofelil GnRH
agonist Trk tyrosine inhibitor GnRH agonist Testosterone Calcitonin
Estrogen Calcitonin Etridonate Calcitonin Pamridonate Octreotide
.alpha.-interferon Octreotide IGF-1 Octreotide Miclodrine GnRH
agonist Flutamide Etofylline Theophylline
[0056] Preferably, the at least one active agent is/are of low to
moderate lipophilicity. More preferably, at least one active agent
has a log octanol/water partition coefficient (log P) (Ruelle and
Kesselring (1998), J Pharm Sci. Vol. 87:1115-24) in the range of
5.0 to -3.0. Most preferred are active agents having a log P value
in the range of 3.0 to -3.0 and, particularly, those having a log P
value in the range of 1.0 to -3.0.
[0057] Log P values for representatives of the abovementioned
classes of active agents are provided in Table 2.
2 TABLE 2 Agent log octanol/water partition (log P) octreotide 1.40
cyclosporin A 2.90 captopril -1.86 trandolaprilate 1.02
perindoprilate -0.36 quinaprilate 0.69 morphine 0.76 lidocaine 2.26
methadone 3.93 promethazine 4.75 indomethacin 4.27 flufenamic acid
1.14 phenylbutazone 3.16 theophylline -0.02 etofylline 0.35 TRH
-2.40
[0058] The pore-forming agent may be any agent or combination of
agents which enables the sustained release of the at least one
active agent from the stearin excipient, with the proviso that when
the at least one active agent is a GnRH agonist(s) the pore-forming
agent is not lecithin.
[0059] Preferably, the pore-forming agent or agents is/are selected
from water-soluble agents such as inorganic salts (e.g. chlorides,
phosphates and sulphates), organic salts (e.g. acetates, formates,
propionates, glutamates, and aspartates), sugars (e.g. glucose,
trehalose, mannose, galactose, sucrose and low molecular weight
carbohydrates such as hydroxy propyl methylcellulose (HPMC) and
carboxy methylcellulose (CMC)), aminosugars (e.g. glucosamine and
galactosamine), amino acids/peptides (e.g. lysine, arginine,
glutamic acid, aspartic acid, carnosine and aspartame),
water-soluble proteins and water-soluble vitamins (e.g. Vitamin
B).
[0060] Presently, the most preferred pore-forming agent is lecithin
(except where the at least one active agent is a GnRH agonist(s))
and the amino acid lysine. Lecithin is a mixture of diglycerides of
stearic, palmitic and oleic acids linked to the choline ester of
phosphoric acid. The efficacy of lecithin as a pore-forming agent
in a sustained release formulation comprising deslorelin and
stearin is described in International patent application No.
PCT/AU96/00370 (WO 97/00693), the entire disclosure of which is
incorporated herein by reference.
[0061] As will be evident from the examples herein, variation of
the identity and/or amount of the pore-forming agent(s) utilised
allows for the manipulation of the release profile of the active
agent(s) to suit particular therapeutic uses.
[0062] The stearin excipient is preferably in a non-crystalline
form. Stearin is partially hydrogenated palm oil having, as the
principle fatty acids, C16:0(45%) and C18:0(53%). The melting point
of stearin is about 60.degree. C. It is believed that the use of
stearin as the excipient contributes to the success of the
formulations according to the invention, because it appears,
surprisingly, to produce only a minimal to mild inflammatory
response in a recipient resulting in the encapsulation of the
formulation within a thin layer of fibroblasts. It will be
appreciated by persons skilled in the art, that alternative
formulations comprising excipient(s) with similar characteristics
to those included in the formulation defined above in the first
aspect may likewise provoke minimal to mild inflammatory responses
and consequently be useful for the sustained-release of an active
agent(s). Such alternative formulations are to be regarded as
falling within the scope of the present invention.
[0063] The formulations according to the invention may be for
administration to humans and other animals selected from dogs,
cats, other domestic animals, and captive wildlife.
[0064] Typically, the formulations will release the active
agent(s), in vitro, into phosphate buffered saline (PBS: pH 7.3,
prepared by dissolving 8.00 g of sodium chloride, 1.00 g di-sodium
hydrogen phosphate anhydrous, 0.40 g sodium dihydrogen phosphate
dihydrate (0.31 g if anydrous), and 0.05 g sodium azide in 1 litre
of deionised water), at 37.degree. C. at a rate of about 2-350
.mu.g/day for at least 7 days and up to about 2 years.
[0065] Further, the formulations will typically exist as a depot
formulation for example in the form of free flowing beads or rods
which may have been extruded.
[0066] Extruded rods may be cut into predetermined lengths for
implantation by standard techniques, in a human or other animal. As
will be readily appreciated, the length of the rod will determine
the rate and dose of the active agent(s). As opposed to implanting
longer rods more than one rod can be implanted in each human or
other animal. Injection of a suspension of formulated particulate
material such as free flowing beads may also deliver the active
agent(s) at the desired rate and dose.
[0067] Formulations for administration as free flowing beads and/or
implants, particularly to dogs, may be produced as follows:
[0068] Stearin (supplied as free flowing beads of 1 mm or less in
diameter made by Vandenberg Foods) and pore-forming agent are
mixed. The active agent may then be added and thoroughly mixed into
the excipient and pore-forming agent mixture. This material may
then be used for injection. Alternatively the mixture can be
transferred to the barrel of a ram extruder that has a 1 mm nozzle
attached and is equilibrated to 55.degree. C. (or other temperature
sufficient to soften the stearin). After attaching the ram,
pressure (40 psi) is applied until the product begins to extrude.
At this point the pressure can be backed off and the product
allowed to reach 55.degree. C. (or other temperature sufficient to
soften the stearin). The product may then be extruded at, for
example, a rate of 3 g over a 30 second period. The resulting
extrudate is then allowed to cool and then broken up and
re-extruded through a 1 mm nozzle to ensure uniformity of content
throughout the mix. The 1 mm nozzle may then be replaced with a 2.3
mm diameter nozzle and the product extruded (using the same
temperature equilibration procedure prior to extrusion). After
cooling the long rods produced can be sectioned into lengths of the
required weight and the sectioned lengths sterilised by
gamma-irradiation.
[0069] Alternatively, formulations for administration as
bioimplants, particularly for dogs, may be produced by:
[0070] Stearin and pore-forming agent are mixed. The active agent
may then be added and thoroughly mixed into the excipient and
pore-forming agent mixture. The mixture can then be transferred to
the barrel of an extruder that has a 2.3 mm nozzle attached and
which has been equilibrated to a temperature sufficient to soften
the stearin. The extruder is started and the product begins to
extrude and the extrudate is cut to length. The sectioned length
can be terminally sterilised.
[0071] Further, in preparing formulations according to the present
invention, especially where the at least one active agent is a
peptide(s), polypeptide(s) or protein(s), it is preferred that the
at least one active agent is firstly pre-treated with a process
comprising at least two freeze drying steps. Such freeze drying
steps may be conducted in accordance with any of the commonly known
methods for freeze drying of proteinaceous materials. It is,
however, preferred that the active agent(s) be freeze dried from a
5-50% (more preferably, 5-15%) (w/w) solution of the active
agent(s) in a suitable solvent (e.g. an alcohol solution such as
30% (w/w) ethanol in water). The freeze dried active agent(s) may
then be redissolved or homogenised in a suitable solvent (e.g.
25-75% (w/w) in a diluted weak acid solution such as 1-5 % (w/w)
acetic acid in water) and subsequently freeze dried again. Thus,
the freeze drying of the active agent(s) may comprise the steps
of;
[0072] (i) forming a 5-50% (w/w) solution of the active
agent(s),
[0073] (ii) freeze drying said solution of step (i),
[0074] (iii) forming a 25-75% (w/w) solution or homogenate from
said freeze dried active agent(s), and
[0075] (iv) freeze drying said solution or homogenate of step
(iii).
[0076] The term "on an active basis" is to be given its usual
meaning in the art. That is, it is used to indicate that the %
amount (w/w) of peptide agonist or analogue present in a
formulation is based on the dry weight of the peptide agonist or
analogue.
[0077] The terms "comprise", "comprises" and "comprising" as used
throughout the specification are intended to refer to the inclusion
of a stated step, component or feature or group of steps,
components or features with or without the inclusion of a further
step, component or feature or group of steps, components or
features.
[0078] The invention will hereinafter be further described by
reference to the following, non-limiting examples and accompanying
figures.
BRIEF DESCRIPTION OF THE ACCOMPANYING FIGURES
[0079] FIG. 1 provides a graph showing average daily in vitro
release profiles from three 100 mg rods of each of formulations:
(I) 6% deslorelin, 2% lysine and balance stearin; and (II) 6%
deslorelin, 5% lysine and balance stearin. The graph demonstrates
an initial rapid release of the active agent and then continued
release extending over a prolonged period (110 days).
[0080] FIG. 2 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations:
(III) 6% deslorelin, 2% sodium sulphate and balance stearin; and
(IV) 6% deslorelin, 5% sodium sulphate and balance stearin. The
graph demonstrates that a greater initial rapid release of
deslorelin (534 .mu.g vs. 438 .mu.g) was achieved using 5% sodium
sulphate as the pore-forming agent. After the initial rapid release
(finished at about day 10), the rate of release was about 10-2
.mu.g/day for the next 95 days for both formulations.
[0081] FIG. 3 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations: (V)
6% deslorelin, 2% hydroxy propyl methylcellulose (HPMC) and balance
stearin; and (VI) 6% deslorelin, 5% hydroxy propyl methylcellulose
(HPMC) and balance stearin.
[0082] The graph demonstrates that a much greater initial rapid
release of deslorelin (685 .mu.g vs. 403 .mu.g) was achieved using
5% HPMC as the pore-forming agent. After the initial rapid release
(finished at about day 10), the rate of release was about 10-2
.mu.g/day for the next 95 days for both formulations.
[0083] FIG. 4 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations:
(VII) 6% deslorelin, 2% glucose and balance stearin; and (VM) 6%
deslorelin, 5% glucose and balance stearin. The graph demonstrates
that a much greater initial rapid release of deslorelin (790 .mu.g
vs. 403 .mu.g) was achieved using 5% glucose as the pore-forming
agent. After the initial rapid release (finished at about day 10),
the rate of release was about 50-2 .mu.g/day for the next 95 days
for both formulations.
[0084] FIG. 5 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations:
(IX) 6% soinatostatin, 0% acetate and balance stearin; (X) 6%
somatostatin, 3% acetate and balance stearin; (XI 6% soniatostatin,
5% lysine and balance stearin; and (XII) 6% somatostatin, 10%
lysine and balance stearin. The graph demonstrates that a greater
initial rapid release of somatostatin was achieved using lysine
than sodium acetate as the pore-forming agent After the initial
rapid release (finished at about day 2), the rate of release in all
cases slowed and plateaued by day 7.
[0085] FIG. 6 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations:
(XIII) 6% naltrexone (NX), 0% pore forming agent and balance
stearin; (XIV) 6% iialtiexone (NX), 3%/o acetate and balance
stealin; (XV) 6% naltrexone (NX), 5% lysine and balance stearin:
and (XVI) 6% naltiexonie (NX), 10% lysine and balance stearin. The
graph demonstrates that a sustained gradual release of iialtrexone
was achieved by all formulations over 23 days of testing, although
the average daily release was low when no pore-forming agent was
included.
[0086] FIG. 7 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations:
(XVII) 6% lisinopril, 0% sodium acetate and balance stearin;
(XVIII) 6% lisinopril, 3% sodium acetate and balance stearin; (XIX)
6% lisinopril, 5% lysine and balance stearin; and (XX) 6%
lisinopril, 10% lysine and balance stearin. The graph demonstrates
that following an initial rapid release (finished at about day 1) a
sustained gradual release of lisinopril was achieved by all
formulations over 25 days of testing, although the average daily
release of this period of sustained release was low in the case of
formulation XVII (i.e. 0% pore-forming agent).
[0087] FIG. 8 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of each of formulations:
(XXI) 6% thyrotropin releasing hormone (TRH), 0% acetate and
balance stearin; (XXII) 6% thyrotropin releasing hormone (TRH), 3%
acetate and balance stearin; (XXIII) 6% thyrotropiii releasing
hormone (TRH), 5% lysine and balance stearin; and (XXIV) 6%
thyrotropin releasing hormone (TrRH), 10% lysine and balance
stearin. The graph demonstrates that following a very rapid initial
release, a sustained gradual release of TRH was achieved with
formulations XXII, XXII and XXIV over the 28 day period of of
testing Where no pore-forming agent was included, no further TRH
release was observed after day 1.
[0088] FIG. 9 provides a graph showing the average daily in vitro
release profile from three 100 mg rods of formulation: (XXV) 6%
deslorelin, 3% sodium acetate and balance stearin. The graph
demonstrates that sustained release of deslorelin over 110 days was
achieved.
EXAMPLES
[0089] Formulations Comprising deslorelin and Lysine
[0090] Formulations I and H (detailed above) were prepared as
follows:
[0091] Stearin (supplied as free flowing beads of 1 mm or less in
diameter made by Quest International Pty Ltd (Netherlands) and
lecithin (supplied as a deep brown viscous syrup from Lucas Myer
(Germany) were hand mixed using a spatula in a small beaker.
Deslorelin (Bacheni, Switzerland) pre-treated by the above
described freeze drying process, was then added and thoroughly
mixed into the excipients. The mixed material was transferred to
the barrel of a ram extruder that has a 1 mm nozzle attached and is
equilibrated to 55.degree. C. The ram extrusion pressure was 40
psi. The ram was attached and pressure applied until the product
began to extrude. At this point the pressure was backed off and the
product allowed to reach 55.degree. C. The product was then
extruded at a rate of 3 g over a 30 second period. The resulting
exudate was allowed to cool and then broken up and re-extruded
through a 1 mm nozzle. This step was included to ensure uniformity
of content throughout the matrix. The 1 mm nozzle was then replaced
with a 2.3 mm diameter nozzle. The same product temperature
equilibration procedure was conducted prior to extrusion. The
product was then extruded and after cooling the long rods produced
were sectioned into lengths of the required weight.
[0092] FIG. 1 provides results of in vitro deslorelin release with
100 mg rods containing 6 mg deslorelin. The assay involved
immersing each rod into separate containers with 1 ml of phosphate
buffered saline (PBS; as hereinbefore described) placed in a
reciprocating water bath at 37.degree. C. The PBS was replaced
daily and the withdrawn PBS assayed for deslorelin with HPLC. The
figure shows that after an initial rapid release of deslorelin,
sustained release extending over a prolonged period (110 days) was
achieved. The average daily rate of deslorelin release during the
sustained release period was within the range 50-2 .mu.g/day.
[0093] Formulations Comprising Deslorelin and Sodium Sulphate
[0094] Formulations III and IV were prepared with sodium sulphate
(Ajax Chemicals, USA) as the pore-forming agent in the same manner
as described to above for deslorelin/lysine formulations.
[0095] FIG. 2 provides results of in vitro deslorelin release with
100 mg rods containing 6 mg deslorelin. The figure shows that a
greater initial rapid release of deslorelin (534 .mu.g vs. 438
.mu.g) was achieved using a 5% concentration of sodium sulphate
rather than a 2% concentration. After the initial rapid release
(finished at about day 10), the rate of release was about 10-2
.mu.g/day for the next 95 days for both formulations.
[0096] Formulations Comprising Deslorelin and HPMC
[0097] Formulations V and VI were prepared with hydroxy propyl
methylcellulose (HPMC) as the pore-forming agent in the same manner
as described above for deslorelin/lysine formulations.
[0098] FIG. 3 provides results of in vitro deslorelin release with
100 mg rods containing 6 mg desloelin. The figure shows that a much
greater initial rapid release of deslorelin (685 .mu.g vs. 403
.mu.g) was achieved using 5% PMC rather than 2% HPMC. After the
initial rapid release (finished at about day 10), the rate of
release was about 10-2 .mu.g/day for the next 95 days for both
formulations.
[0099] Formulations Comprising Deslorelin and Glucose
[0100] Formulations VII and VIII were prepared with glucose (Ajax
Chemicals, USA) as the pore-forming agent in the same manner as
described above for deslorelin/lysine formulations.
[0101] FIG. 4 provides results of in vitro deslorelin release with
100 mg rods, containing 6 mg deslorelin. The figure shows that a
much greater initial rapid release of deslorelin (790 .mu.g vs. 403
.mu.g) was achieved using 5% glucose rather than 2% glucose as the
pore-forming agent. After the initial rapid release (finished at
about day 10), the rate of release was about 50-2 .mu.g/day for the
next 95 days for both formulations.
[0102] Formulations Comprising Somatostatin and Sodium Acetate or
Lysine
[0103] Formulations IX to XII were prepared with sodium acetate or
lysine as the pore-forming agent in a manner similar to that
described above for deslorelin/lysine formulations. The
somatostatin was obtained from Bachem (Switzerland).
[0104] FIG. 5 provides results of in vitro somatostatin release
with 100 mg rods, containing 6 mg somatostatin. The figure shows
that a greater initial rapid release of somatostatin was achieved
using lysine than sodium acetate as the pore-forming agent.
[0105] Formulations Comprising Naltrexone and Sodium Acetate or
Lysine
[0106] Formulations XIII to XVI were prepared with sodium acetate
or lysine as the pore-forming agent in a manner similar to that
described above for deslorelin/lysine formulations.
[0107] FIG. 6 provides results of in vitro naltrexone release with
100 mg rods, containing 6 mg deslorelin. The figure shows that a
sustained gradual release of naltrexone was achieved by all
formulations over 23 days of testing, although the average daily
release was low when no pore-forming agent was included.
[0108] Formulations Comprising Lisinopril and Sodium Acetate or
Lysine
[0109] Formulations XVII to XX were prepared with sodium acetate or
lysine as the pore-forming agent in a manner similar to that
described above for deslorelin/lysine formulations. The lisinopril
was obtained from Sigma Chemical Co. (USA).
[0110] FIG. 7 provides results of in vitro lisinopril release from
100 mg rods, containing 6 mg lisinopril. The figure shows that
following an initial rapid release (finished at about day 1) a
sustained gradual release of lisinopril was achieved by all
formulations over 25 days of testing, although the average daily
release of this period of sustained release was low in the case of
formulation XVII which contains no pore-forming agent.
[0111] Formulations Comprising TRH and Sodium Acetate or Lysine
[0112] Formulations XX to XXIV were prepared with sodium acetate or
lysine as the pore-forming agent in a manner similar to that
described above for deslorelin/lysine formulations. The TRH was
obtained from Sigma Chemical Co (USA).
[0113] FIG. 8 provides results of in vitro TRH release from 100 mg
rods, containing 6 mg TRH. The figure shows that following a very
rapid initial release, a sustained gradual release of TRH was
achieved with formulations XXII, XXII and XXV over the 28 day
period of of testing Where no pore-forming agent was included, no
further TRH release was observed after day 1.
[0114] Formulations Comprising Deslorelin and Sodium Acetate
[0115] Formulation XXV were prepared with sodium acetate as the
pore-forming agent in the same manner as described above for
deslorelin/lysine formulations.
[0116] FIG. 9 provides results of in vitro deslorelin release with
6 mg rods. The figure shows that sustained release of deslorelin
over 110 days was achieved.
[0117] It will be appreciated by persons skilled in the art that
numerous variations and/or modifications may be made to the
invention as shown in the specific embodiments without departing
from the spirit or scope of the invention as broadly described. The
present embodiments are, therefore, to be considered in all
respects as illustrative and not restrictive.
Sequence CWU 1
1
16 1 10 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 1 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa 1
5 10 2 9 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 2 Xaa His Trp Ser Tyr Xaa Leu Arg Xaa 1 5 3
9 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 3 Xaa His Trp Ser Tyr Xaa Leu Arg Xaa 1 5 4
10 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 4 Xaa His Trp Ser Tyr Xaa Leu Arg Pro Xaa 1
5 10 5 9 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 5 Xaa His Trp Ser Tyr Xaa Leu Arg Xaa 1 5 6
9 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 6 Xaa His Trp Ser Tyr Xaa Leu Arg Xaa 1 5 7
9 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 7 Pro His Trp Ser Tyr Xaa Leu Arg Xaa 1 5 8
9 PRT Artificial Sequence Description of Artificial Sequence
Synthetic GnRH agonist 8 Xaa His Trp Ser Tyr Xaa Leu Arg Xaa 1 5 9
8 PRT Artificial Sequence Description of Artificial Sequence
Synthetic substance P antagonist 9 Pro Gln Gln Phe Phe Gly Leu Met
1 5 10 7 PRT Artificial Sequence Description of Artificial Sequence
Synthetic substance P antagonist 10 Gln Gln Phe Phe Gly Leu Met 1 5
11 6 PRT Artificial Sequence Description of Artificial Sequence
Synthetic substance P antagonist 11 Gln Phe Phe Gly Leu Met 1 5 12
5 PRT Artificial Sequence Description of Artificial Sequence
Synthetic substance P antagonist 12 Phe Phe Gly Leu Met 1 5 13 4
PRT Artificial Sequence Description of Artificial Sequence
Synthetic substance P antagonist 13 Phe Gly Leu Met 1 14 3 PRT
Artificial Sequence Description of Artificial Sequence Synthetic
substance P antagonist 14 Gly Leu Met 1 15 7 PRT Artificial
Sequence Description of Artificial Sequence Synthetic galanin
fragment peptide 15 Pro Pro Ala Leu Ala Leu Ala 1 5 16 4 PRT
Artificial Sequence Description of Artificial Sequence Synthetic
thyrotropin releasing hormone analogue 16 Xaa His Pro Gly 1
* * * * *